Redcare Pharmacy Shares: A Cautious Rebound Amid Policy Shifts

Redcare Pharmacy shares surge over 20% as a German proposal to raise drug co-payments and a short squeeze fuel a major MDAX rally, despite a challenging year-to-date performance.

Shares of Redcare Pharmacy surged by over 20% across just two trading sessions, marking one of the most significant moves within Germany's MDAX index in recent weeks. This sharp appreciation was fueled by a confluence of two powerful market forces: a new policy proposal from the German government and a technical squeeze on bearish investors.

A Policy-Driven Catalyst

The initial spark came from the realm of healthcare policy. A key financial commission has proposed raising co-payments for prescription medications by 50%. This would increase the current range of 5 to 10 euros per prescription to a new bracket of 7.50 to 15 euros. Federal Health Minister Nina Warken has indicated that corresponding legislative procedures will be initiated promptly.

Market experts, including Metzler Bank analyst Felix Dennl, interpret this as a clear tailwind for online pharmacies. Higher out-of-pocket expenses are expected to drive price-sensitive patients away from traditional brick-and-mortar pharmacies and toward more cost-effective online alternatives. This potential shift is further amplified by a standing ruling from the European Court of Justice, which states that EU-registered online pharmacies are not bound by Germany's fixed pricing for prescription drugs. This structural advantage is seen as reinforcing Redcare's competitive position.

Technical Factors Amplify Gains

The intensity of the stock's rise was exacerbated by its prior market positioning. Redcare had been heavily targeted by short sellers, with many traders betting on a continued decline. The announcement of the reform plans triggered a wave of covering, as these short sellers were compelled to buy back shares to close their positions. This mechanism, known as a short squeeze, can dramatically accelerate upward momentum in stocks with significant short interest.

Despite this powerful rebound, the broader performance picture remains challenging. Since the start of the year, the share price is still down approximately 44%, placing it second-to-last in the MDAX rankings for 2026. Only the used-car platform Auto1 Group has performed worse.

A Stable Prescription Business

In its core prescription medication segment, Redcare maintains a structurally sound foundation. Competitor Rossmann has confirmed that its planned online pharmacy will not offer prescription drugs. Leveraging its CardLink license, valid until January 2027, and the integration of the GesundheitsID (Health ID), Redcare is targeting Rx revenue exceeding 670 million euros for 2026.

Forthcoming Milestones Under Scrutiny

Investor attention now turns to two imminent events. On April 15, 2026, the annual general meeting will officially appoint Hendrik Krampe as the new Chief Financial Officer. This will be followed on May 6, 2026, by the release of the first quarterly report under the new leadership. This report is anticipated to provide the first concrete evidence of whether the company's recently initiated strategic realignment is beginning to yield results.